Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. announced that its Compensation Committee approved the grant of restricted stock units (RSUs) to 118 new non-executive employees.
Stocks · News reference
Filed: 2026-11-16 AccNo: 0001193125-26-463573 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guardant Health, Inc. announced that its Compensation Committee approved the grant of restricted stock units (RSUs) to 118 new non-executive employees.
Guardant Health has secured approval from the Ministry of Health and Welfare (MOHW) in Taiwan for its Laboratory Developed Test Services (LDTS).
Guardant Health, Inc. has priced a private offering of $500 million in 0% convertible senior notes due 2032 to qualified institutional buyers.
Guardant Health, Inc. has announced its intention to offer $500.0 million in aggregate principal amount of convertible senior notes due 2032 in a private offering.
Guardant Health has launched new epigenomic applications for its Guardant360® Liquid test, providing oncologists with enhanced insights for treatment selection in patients lacking traditional biomarkers.
Guardant Health reported that the journal ESMO Open has published results from the PRECISION study, which evaluated blood-based approaches for assessing recurrence risk in colorectal cancer patients.